Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Severe or critical case 85% Improvement Relative Risk c19early.org/d Dror et al. Vitamin D for COVID-19 Sufficiency Are vitamin D levels associated with COVID-19 outcomes? Retrospective 253 patients in Israel Lower severe cases with higher vitamin D levels (p=0.0013) Dror et al., PLOS ONE, doi:10.1371/journal.pone.0263069 Favors vitamin D Favors control
Pre-infection 25-hydroxyvitamin D3 levels and association with severity of COVID-19 illness
Dror et al., PLOS ONE, doi:10.1371/journal.pone.0263069 (date from earlier preprint)
Dror et al., Pre-infection 25-hydroxyvitamin D3 levels and association with severity of COVID-19 illness, PLOS ONE, doi:10.1371/journal.pone.0263069 (date from earlier preprint)
Jun 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 253 hospitalized patients in Israel showing higher mortality and higher risk of severe cases with vitamin D deficiency. Vitamin D levels were measured 14 to 730 days before the COVID-19 test. Adjusted results are only provided for severity.
risk of severe or critical case, 84.8% lower, RR 0.15, p = 0.001, high D levels 109 of 120 (90.8%), low D levels 76 of 133 (57.1%), adjusted per study, inverted to make RR<1 favor high D levels, odds ratio converted to relative risk, >40ng/mL vs. <20ng/mL, multivariable.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Dror et al., 7 Jun 2021, retrospective, Israel, peer-reviewed, 18 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Abstract: PLOS ONE RESEARCH ARTICLE Pre-infection 25-hydroxyvitamin D3 levels and association with severity of COVID-19 illness Amiel A. Dror ID1,2*, Nicole Morozov ID3, Amani Daoud1,2, Yoav Namir2, Orly Yakir4, Yair Shachar1, Mark Lifshitz5, Ella Segal1,2, Lior Fisher1,2, Matti Mizrachi1,2, Netanel Eisenbach1,2, Doaa Rayan1,2, Maayan Gruber1,2, Amir Bashkin2,6, Edward Kaykov2,7, Masad Barhoum8, Michael Edelstein2, Eyal Sela1,2 1 Department of Otolaryngology, Head and Neck Surgery, Galilee Medical Center, Nahariya, Israel, 2 Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel, 3 Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, 4 Statistical Analysis Division, Galilee Medical Center, Nahariya, Israel, 5 Computer Data Division, Galilee Medical Center, Nahariya, Israel, 6 Endocrinology Unit, Galilee Medical Center, Nahariya, Israel, 7 Geriatric Medicine Department, Galilee Medical Center, Nahariya, Israel, 8 Galilee Medical Center, Nahariya, Israel a1111111111 a1111111111 a1111111111 a1111111111 a1111111111 * amieldror@gmail.com Abstract Objective OPEN ACCESS Citation: Dror AA, Morozov N, Daoud A, Namir Y, Yakir O, Shachar Y, et al. (2022) Pre-infection 25hydroxyvitamin D3 levels and association with severity of COVID-19 illness. PLoS ONE 17(2): e0263069. https://doi.org/10.1371/journal. pone.0263069 Editor: Dong-Yan Jin, University of Hong Kong, HONG KONG Received: June 27, 2021 Accepted: January 12, 2022 Published: February 3, 2022 Copyright: © 2022 Dror et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Data Availability Statement: All relevant data are within the manuscript and its Supporting Information files. Funding: The author(s) received no specific funding for this work. Competing interests: The authors have declared that no competing interests exist. Studies have demonstrated a potential correlation between low vitamin D status and both an increased risk of infection with SARS-CoV-2 and poorer clinical outcomes. This retrospective study examines if, and to what degree, a relationship exists between pre-infection serum 25-hydroxyvitamin D (25(OH)D) level and disease severity and mortality due to SARS-CoV-2. Participants The records of individuals admitted between April 7th, 2020 and February 4th, 2021 to the Galilee Medical Center (GMC) in Nahariya, Israel, with positive polymerase chain reaction (PCR) tests for SARS-CoV-2 (COVID-19) were searched for historical 25(OH)D levels measured 14 to 730 days prior to the positive PCR test. Design Patients admitted to GMC with COVID-19 were categorized according to disease severity and level of 25(OH)D. An association between pre-infection 25(OH)D levels, divided between four categories (deficient, insufficient, adequate, and high-normal), and COVID-19 severity was ascertained utilizing a multivariable regression analysis. To isolate the possible influence of the sinusoidal pattern of seasonal 25(OH)D changes throughout the year, a cosinor model was used. Results Of 1176 patients admitted, 253 had records of a 25(OH)D level prior to COVID-19 infection. A lower vitamin D status was more common in patients with the severe or critical disease (<20 ng/mL [87.4%]) than in individuals with mild or moderate disease (<20 ng/mL [34.3%] p PLOS ONE |..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit